SBIR/STTR Research Award

Ultra-sensitive rapid test for detecting bacterial contamination in platelets

Award identifier 019c64b71c1ce297cf916d3efeefa3fa727570599994bc73ff338cc48403ed12Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$265,092

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Photon Biosciences LLC
Proposal award date
2020-05-12
Contract end date
2020-10-31
UEI
H4E3QZYNTHD1
Solicitation number
PA19-272
Topic code
NIAID

Research abstract

Project Abstract Over the past several years, bacterial contamination of platelets has been the greatest transfusion-transmitted infectious risk in the United States. Bacterial contamination of platelet components occurs because of its unavoidable storage temperature (22 °C), resulting in recognized transfusion-transmitted sepsis in at least 1 of 100,000 recipients, and an immediate fatal outcome in 1 in 500,000 recipients. Currently, the gold-standard tests for bacterial contamination of platelets rely on limulus amebocyte lysate (LAL), the aqueous extract of the blood of horseshoe crabs, which forms a clot or gel upon exposure to bacterial endotoxin. Due to the unsustainability of the LAL method, several new alternative technologies using chromogenic, chemifluorescent, or chemiluminescent assays have been introduced into the market; however, they continue to have serious limitations in terms of performance and spectroscopic range (both in time and wavelength). Photon Biosciences, LLC and S2Media (S2M Enterprises, LLC) have engineered a new, non-photobleaching luminescent protein named RECAL®, which we intend to use as the basis for a fully quantitative, highly sensitive, rapid assay kit for checking for bacterial contamination of platelets.Project narrative Bacterial contamination of platelets and the consequential septic reactions have been the greatest transfusion-transmitted infectious risk, morbidity and mortality in the United States (CDC), and the risk becomes even greater because platelets have to be stored at room temperature. A sensitive test is urgently needed to detect bacterial contamination early enough to mitigate transfusion- transmitted infections significantly. RECAL®, a new, ultrasensitive, non-bleaching luminescent detection platform, can be effectively applied to detect bacterial contamination in platelets at low levels and holds great promise to act as the cornerstone of ultrasensitive probes for detecting early-stage bacterial contamination.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

4 SBIR/STTR records share this UEI (2018–2024). Reported award amounts total $1,014,129. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.